ロード中...
Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
The approval of upfront abiraterone for castration-sensitive prostate cancer and the approval of enzalutamide and apalutamide for non-metastatic castration-resistant prostate cancer have led to early utilization of potent androgen receptor (AR) signaling inhibitors in treating advanced prostate canc...
保存先:
| 出版年: | Cells |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6721701/ https://ncbi.nlm.nih.gov/pubmed/31404966 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells8080860 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|